A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
This study is a multicenter, open-label study to evaluate the effectiveness and safety of MEDI4736 as a single agent or in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma whose disease has progressed on fluoropyrimidine-containing or gemcitabine-containing first-line chemotherapy.
MEDI4736 is an anti-PD-L1 monoclonal antibody. Tremelimumab is an anti-CTLA4 monoclonal antibody. Both are given by intravenous infusion.
To be eligible for this study, patients must:
- Have metastatic pancreatic ductal adenocarcinoma
- Have not had more than one prior chemotherapy regimen
- Have an ECOG status of 0 or 1.
- Be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Eileen O'Reilly at 646-888-4182.